1. Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial

2. Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis

3. Regional variation in characteristics of patients with decompensated cirrhosis admitted to hospitals in the UK

4. Defining and characterising a toolkit for the development of a successful European registry for rare liver diseases: a model for building a rare disease registry

5. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches

6. Epidemiology of HPB malignancy in the elderly

7. Improving uptake of hepatitis B and hepatitis C testing in South Asian migrants in community and faith settings using educational interventions-A prospective descriptive study

8. Clinical Ontologies Improve Case Finding of Primary Biliary Cholangitis in UK Primary and Secondary Care

9. The role of the chronic care model in promoting the management of the patient with rare liver disease

10. Pregnancy-associated liver disease: a curriculum-based review

11. Interventions to improve the uptake of screening across a range of conditions in Ethnic Minority Groups: a systematic review

12. Wilson disease: more than meets the eye

13. The clinical management of hereditary haemochromatosis

14. Well-differentiated bronchial neuroendocrine tumors: Clinical management and outcomes in 105 patients

15. Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency

16. Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases

17. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations

18. Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes

19. Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor

20. The role of dietary factors in prevention and progression of breast cancer

21. Prostate cancer and the influence of dietary factors and supplements: a systematic review

22. The impact of diet and nutrition in the prevention and progression of hepatocellular carcinoma

23. Nutrition and pancreatic cancer

24. Diet and supplements and their impact on colorectal cancer

25. Using an 'action set' for the management of acute upper gastrointestinal bleeding

26. Pancreatic adenocarcinoma in a patient with multiple endocrine neoplasia 1 syndrome

27. Appendiceal goblet cell carcinoid tumour: a case of unexpected lung metastasis

28. Gastric mixed adenoneuroendocrine carcinoma with a trilineage cell differentiation: case report and review of the literature

29. Hepatobiliary disease associated with hypereosinophilia: a report of two patients and a review of the literature

​

​

​

​​

1. Hepatocellular Carcinoma (HCC) Management in a Tertiary HPB Centre- Lessons from the South East Coast of the UK. D’Souza D, Ionescu A, Hamzah B, Pydisetty G, Mathew S, Pericleous M. EASL Liver Cancer Summit 2023, Portugal.

2. Using a Novel Ontology to Improve Case-Finding of Primary Biliary Cholangitis (PBC) in the Patient Database of the Royal College of General Practitioners (RCGP) of the United Kingdom (UK)-Implications for Early Diagnosis and Management. Pericleous M, Kelly C, McGee C, Sherlock J, Yonova I, Byford R, Ferreira F, de Lusignan S, Ala A. AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) meeting, San Francisco 2018.

3. Patient Registries for Orphan Liver Diseases; Translating Policy to Real World in Member States of the European Union Pericleous M, Kelly C, de Lusignan S, Ala A.AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) meeting, San Francisco 2018

4. Developing a Novel Real-World South East England Registry for Primary Biliary Cholangitis (PBC) Allowing Data-Linkage from Primary to Secondary Care - Preliminary Findings from a UK National Institute for Health Research (NIHR) Portfolio Study. Pericleous M, Kelly C, de Lusignan S, Ala A. AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) meeting, San Francisco 2018

5. A novel educational intervention for chronic viral hepatitis (CVH) case-finding in UK South-Asians, a high-risk UK population: preliminary results from a National Institute for Health Research (NIHR) feasibility study. Kelly C, , Ahmed A, Hendy J, Vandrevala T, Mathew D, de Lusignan S, Ala A. AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) meeting, San Francisco 2018

6. Non-alcoholic fatty liver disease (NAFLD) patients have significantly lower lysosomal acid lipase (LAL) activity; experience from the Regional South East England Hepatology Clinic. Pericleous M, Kelly C, Wang T, Livingstone C, Ala A. BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting. York 2018.

7. Translating policy to real world in rare liver diseases registries; a European Perspective. Pericleous M, Kelly C, de Lusignan S, Ala A. BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting. York 2018

8. Defining a model blueprint for the development of successful patient registries for rare liver diseases. Pericleous M, Kelly C, de Lusignan S, Ala A. BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting, York 2018

9. Developing a novel real-world South East England registry for primary biliary cholangitis (PBC) allowing data-linkage from primary to secondary care - preliminary findings from a UK National Institute for Health Research (NIHR) Clinical Research Network (CRN) portfolio study. Pericleous M, Kelly C, de Lusignan S, Ala A. BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting, York 2018

10. Characterising linkage from primary to secondary care and exploiting novel ontology approaches in improving UK primary biliary cholangitis (PBC) case-finding strategies – Implications for early diagnosis and management.

11. Pericleous M, Kelly C, McGee C, Sherlock J, Yonova I, Byford R, Ferreira F, de Lusignan S, Ala A. BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting, York 2018

12. A novel educational intervention for chronic viral hepatitis (CVH) case-finding in UK South-Asians, a high-risk UK population: preliminary results from a National Institute for Health Research (NIHR) feasibility study. Kelly C, Pericleous M, Ahmed A, Hendy J, Vandrevala T, Mathew D, de Lusignan S, Ala A. BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting, York 2018

13. Has the NHS England commissioning programme for direct-acting antiviral (DAA) therapy for hepatitis C (HCV) changed our patient cohort? The Surrey operational delivery network (ODN) experience. Kelly C, Pericleous M, Cowan M, Cheent K, Lim G, Mathew S, Chakrabarti G, Ala A, Gallagher M. BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting, York 2018

14. Real World data on significant adverse-events (SAEs) in the age of direct acting anti-virals (DAA) for hepatitis C (HCV): The Surrey ODN experience. Kelly C, Pericleous M, Cowan M, Cheent K, Lim G, Mathew S, Chakrabarti G, Ala A, Gallagher M. BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting, York 2018

15. Defining and Characterising the Blueprint for the Development of a Successful Registry for Rare Liver Diseases. Pericleous M, Kelly C, de Lusignan S, Ala A. UEG meeting Vienna 2018

16. A Novel UK Regional Real-World Registry for Primary Biliary Cholangitis (PBC) Allowing Data Linkage from Primary and Secondary Care. Pericleous M, Kelly C, de Lusignan S, Ala A. UEG meeting Vienna 2018

17. Translating Policy to Real World in Rare Liver Diseases Registries; a European Perspective. Pericleous M, Kelly C, de Lusignan S, Ala A. UEG meeting Vienna 2018

18. Development of an alcohol liaison service: clinical outcomes. Kelly C, Pericleous M, Gartland A, Davies S, Gallagher M. AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) meeting, Washington 2017

19. Antenatal Clinic: The ideal screening platform for alcohol related harm. Kelly C, Pericleous M, Gartland A, Davies S, Gallagher M. AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) meeting, Washington 2017

20. Factors preventing testing for chronic viral hepatitis in UK South-Asians –A novel National Institute for Health Research (NIHR) Study in a high-risk group. Kelly C, Ahmed A, Pericleous M, Hendy J, Vandrevala T, Ala A. AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) meeting, Washington, 2017

21. The chronic care model (CCM) in primary biliary cholangitis (PBC): Time to reconsider our approach. Pericleous M, Kelly C, Ala A, de Lusignan S, BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting; Coventry, 2017

22. Primary Biliary Cholangitis (PBC) - a neglected disease in primary care? Pericleous M, Kelly C, de Lusignan S, Ala A, BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting; Coventry, 2017

23. Antenatal clinic: the ideal screening platform for alcohol-related harm  Pericleous M, BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting; Coventry, 2017

24. Interpretation of low lysosomal acid lipase (LAL) levels in the hepatology and metabolic services Pericleous M, Kelly C, Wang T, Livingstone C, Ala A, BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting; Coventry, 2017

25. Is The Chronic Care Model The Answer To The Unmet Need For Integrated Care In Orphan Liver Diseases?Pericleous M, Kelly C, de Lusignan S, Ala A, BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) meeting; Coventry, 2017

26. Factors preventing testing for chronic viral hepatitis (CVH) in UK south-asians - a novel national institute for health research (NIHR) study to improve recognition of CVH in a high-risk population. Pericleouds M​

27. Development of an alcohol liaison service: clinical outcomes. Kelly C, , Gartland A, Davies S, Gallagher M;

28. What is the meaning of low lysosomal acid lipase (LAL) levels in the hepatology and metabolic clinic?Pericleous M, Kelly C, Wang T, Livingstone C, Ala A; BSG meeting; Manchester, 2017

29. Regional and National understanding of IgG-related disease (IgG4-RD) in the UK- strategic implications in testing and case-finding. Pericleous M, Kelly C, Bagwan I, Karim Y, Worthington T, Karanjia N, Ala A; AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) Meeting Boston, 2016

30. The role of repeat liver biopsies for autoimmune hepatitis (AIH) at a tertiary HPB centre in the south of England, UK: clinical dilemmas and steps for the future. Kelly C, , Matthew S, Redfern O, Ala A;

31. Regional and National understanding of IgG-related disease (IgG4-RD) in the United Kingdom; patterns of testing, case-finding and areas for development. Pericleous M, Kelly C, Bagwan I, Karim Y, Worthington T, Karanjia N, Ala A; BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) Meeting Manchester, 2016

32. The Role of Repeat Liver Biopsies in Autoimmune Hepatitis (AIH) at a Tertiary HPB Centre in South England, UK: Current experience, clinical dilemmas and recommendations. Pericleous M, Kelly C Matthew S, Redfern O, Ala A; BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) Meeting Manchester, 2016

33. Hepatocellular Carcinoma (HCC) Management in a Tertiary HPB Centre covering the South of England: Important lessons in considering widening surveillance. Kelly C, , Dhillon T, Karanjia N, Ala A; BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) Meeting Manchester, 2016

34. Trends of serum IgG4 level testing in a UK tertiary hepatopancreatobiliary (HPB) centre and correlation with the diagnosis of IgG4-related disease. Pericleous M, Kelly C, Bagwan I, Karim Y, Worthington T, Karanjia N, Ala A; Falk Symposium 205 Lucerne, 2016

35. Experience of IgG4-related disease (IgG4-RD) in the UK: an online national survey. Pericleous M, Kelly C, Bagwan I, Karim Y, Worthington T, Karanjia N, Ala A; Falk Symposium 205 Lucerne, 2016. Kelly C, Pericleous M, Dhillon T, Bagwan I, Ala A; Falk Symposium 205 Lucerne, 2016

36. Hepatocellular Carcinoma (HCC): Lessons Learnt in the South East Coast UK- Royal Surrey County Hospital. Kelly C, Pericleous M, Dhillon T, Bagwan I, Ala A; Management Of Hepatocellular Carcinoma (HCC) In A Tertiary HPB Centre- Lessons From The South East Coast-The Royal Surrey County Hospital (RSCH). Kelly C , Pericleous M, Bagwan I, Worthington T, Gallagher M, Tibbs C, Dhillon T, Karanjia N, Ala A; National BSG meeting; Liverpool, 2016.

37. Replacing electrolytes in inpatients: experience from a district general hospital; Buckinghamshire Foundation Forum. Pericleous M, Bayliss R, Goddfrey R

38. Hepatitis B Testing Practice: How widespread is household contact. Mathew S, Pericleous M, Ala A

39. The role of repeat liver biopsies in Autoimmune hepatitis: clinical practice and outcomes. Mathew S, Narang R, Pericleous M, Ala A

40. Hypereosinophilic Autoimmune liver disease: A report of three unusual cases. Pericleous M, Mathew S, Lloyd M, Berry P, Lewis H, Cheent K, Ramu A, Kousparos G, Yousuf K, Ala A.

41. Outcomes Of Increased Dose Of Allopurinol In IBD Patients Who Developed Hepatotoxicity On Low Azathioprine And Allopurinol Co-therapy Treatment. Pericleous M, Abdulrehman A, Bull C, Mackenzie G, Stenner J, Cowan M, Hillman G. BSG meeting 2014 Manchester

42. Hepatic Artery Embolisation in Neuroendocrine Tumours; outcomes from a series of 50 patients Pericleous M, M. Caplin, D. Yu, L. Morgan-Rowe, E. Tsochatzis, C. Toumpanakis. BSG meeting 2013; Glasgow

43. Diagnostic and therapeutic outcomes in goblet cell appendiceal neuroendocrine tumours. A.Baneke, C.Toumpanakis, T.Meyer, ME.Caplin. BSG meeting 2012; Liverpool

44. Bronchial neuroendocrine tumours: A retrospective review of management and outcomes in 116 patients. Pericleous M ,H.Lumgair,J.Reiner,L.Marelli,ME.Caplin,T.Meyer, C.Toumpanakis. Online. ASCO meeting supplement 2012

45. Diagnostic features and management outcomes in bronchopulmonary neuroendocrine tumours: A clinical study of 116 patients. Pericleous M,Toumpanakis.C,Lumgair.H et al. 9th Annual ENETS Conference, 2012 Copenhagen.

46. Goblet Cell Appendiceal Neuroendocrine Tumours: Diagnosis, recurrence rates, treatment and survival: A series of 37 patients. Toumpanakis C,Baneke A, Pericleous M et al. 9th Annual ENETS Conference 2012; Copenhagen.

47. Mixed Adenoneuroendocrine Cancer (MANEC); histology and nuclear medicine imaging. Pericleous M, Caplin ME,Luong TV et al. 9th Annual UKINETS Conference,2011, London

48. Management of Upper Gastrointestinal bleeding; can we do better? Pericleous M, Murray C,Kaul A et al. 4th International SAM Conference,8-9/10/2010;Edinburgh.

49. There will be blood...a complete audit cycle. Pericleous M, C.Murray, M.Hamilton et al. BSG meeting 2011;Birmingham

50. Management of upper gastrointestinal bleeding. Can we do better? Pericleous M,Murray C,Kaul A et al. 4th International SAM meeting. Edinburgh.​

​​​